AI주식인사이트AI Stock Insight
C

에이프릴바이오

397030KOSDAQ자연과학 및 공학 연구개발업

50.9 / 100

Reference Date: 2026-06-10

Financial Score18.5 / 40
News Sentiment14.4 / 25
Momentum8.0 / 20
Disclosure10.0 / 15
AI Analysis: the debt ratio is very low with excellent financial health but PBR raises overvaluation concerns. Plunged 29.4% over the past month, and news sentiment is neutral.

Company InformationBased on 2025 Annual Report

Business Overview

April Bio is a research and development-focused company established in 2013, leveraging human antibody production and protein half-life extension technologies to develop antibody therapeutics and sustained recombinant protein drugs. Utilizing its core HuDVFab library and SAFA platform technologies, the company focuses on developing treatments for autoimmune and inflammatory diseases, generating revenue through global licensing agreements with pharmaceutical companies under its RIPCO business model.

Number of Employees

27people

Average Salary

201.1M KRW

Score Calculation Basis

Detailed Financial Score

PER
—Industry Average 62.704.0Point
PBR
10.08Industry Average 3.240.0Point

3.1x industry avg (risky)

ROE
-10.39Industry Average -32.093.5Point

Well below industry avg

Debt Ratio
0.27Industry Average 7.318.0Point

Half of industry avg (excellent)

Trend 2023~20253.0 / 10 points
Revenue Growth Rate
0.0 / 3

Avg ▼92.1% (1-year basis)

Operating Profit Growth Rate
3.0 / 3

Avg ▲41.5% (2-year basis)

ROE Trend
0.0 / 4

Avg ROE -1.9% (improving, 3yr)

Detailed News Sentiment

2 totalPositive 1Neutral 0Negative 1Average Sentiment Score 57.5

Detailed Momentum

52-week position5.0Point

52w mid range (43%)

Current 41,450Won52-week high 73,30052-week low 16,490
1-month return0.0Point

1m -29.39% (strong drop)

Volume trend3.0Point

Volume flat

Detailed Disclosure

1 totalPositive 0Neutral 1Negative 0
  • Neutral분기보고서 (2026.03)2026-05-15